Clinical implications of microRNAs in cancer

References

• Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T (2011). Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett. 300: 197–204.
   PubMed Web of Science ®Google Scholar
• Altomare DF, Di Lena M, Giuratrabocchetta S (2012). MicroRNA: future perspectives in colorectal cancer. Colorectal Dis. 14: 133–134.
   PubMed Web of Science ®Google Scholar
• Anderson NL, Anderson NG (2002). The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteom. 1: 845–867.
   PubMed Web of Science ®Google Scholar
• Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH (2012). MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J. Transl. Med. 10: 128.
   PubMed Web of Science ®Google Scholar
• Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH, Chen LM, Hsieh CJ, Huang SP (2011). Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin. Cancer Res. 17: 928–936.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69: 89–95.
   PubMed Web of Science ®Google Scholar
• Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, Garcia-Foncillas J, Aranda E (2011). Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenom. J. 11: 429–436.
   PubMed Web of Science ®Google Scholar
• Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ, Rodrigues CM (2009). MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. FEBS J. 276: 6689–6700.
   PubMed Web of Science ®Google Scholar
• Caldas C, Brenton JD (2005). Sizing up miRNAs as cancer genes. Nat. Med. 11: 712–714.
   PubMed Web of Science ®Google Scholar
• Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA 101: 2999–3004.
   PubMed Web of Science ®Google Scholar
• Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334: 1351–1358.
   PubMed Web of Science ®Google Scholar
• Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 102: 13944–13949.
   PubMed Web of Science ®Google Scholar
• Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049–2057.
   PubMed Web of Science ®Google Scholar
• Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B (2013). Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer 132: 1602–1612.
   PubMed Web of Science ®Google Scholar
• Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE (2006). The colorectal microRNAome. Proc. Natl. Acad. Sci. USA 103: 3687–3692.
   PubMed Web of Science ®Google Scholar
• Diaz R, Silva J, Garcia JM, Lorenzo Y, Garcia V, Pena C, Rodriguez R, Munoz C, Garcia F, Bonilla F, Dominguez G (2008). Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chrom. Cancer 47: 794–802.
   PubMed Web of Science ®Google Scholar
• Engelmann JC, Spang R (2012). A least angle regression model for the prediction of canonical and non-canonical miRNA-mRNA interactions. PLoS One 7: e40634.
   Web of Science ®Google Scholar
• Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, Biffoni M, Felli N, Mattia G, Petrini M, Colombo MP, Peschle C, Care A (2008). The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 68: 2745–2754.
   PubMed Web of Science ®Google Scholar
• Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM (2006). MicroRNA expression and function in cancer. Trends Mol. Med. 12: 580–587.
   PubMed Web of Science ®Google Scholar
• Garzon R, Marcucci G, Croce CM (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9: 775–789.
   PubMed Web of Science ®Google Scholar
• Gorur A, Balci Fidanci S, Dogruer Unal N, Ayaz L, Akbayir S, Yildirim Yaroglu H, Dirlik M, Serin MS, Tamer L (2013). Determination of plasma microRNA for early detection of gastric cancer. Mol. Biol. Rep. 40: 2091–2096.
   PubMed Web of Science ®Google Scholar
• Goto Y, Yue L, Yokoi A, Nishimura R, Uehara T, Koizumi S, Saikawa Y (2001). A novel single-nucleotide polymorphism in the 3’-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin. Cancer Res. 7: 1952–1956.
   PubMed Web of Science ®Google Scholar
• Gu H, Guo X, Zou L, Zhu H, Zhang J (2013). Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol. Cell. Biochem. 375: 23–30.
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q, Deiters A (2008). Small-molecule inhibitors of microrna miR-21 function. Angew. Chem. Int. Ed. Engl. 47: 7482–7484.
   PubMed Web of Science ®Google Scholar
• Hanke M, Hoefig K, Merz H, Feller A, Kausch I, Jocham D, Warnecke JM, Sczakiel G (2010). A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 28: 655–661.
   PubMed Web of Science ®Google Scholar
• He J, Efron JE (2011). Screening for colorectal cancer. Adv. Surg. 45: 31–44.
   PubMedGoogle Scholar
• Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15: 673–682.
   PubMed Web of Science ®Google Scholar
• Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN, Wang X (2009). A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol. Oncol. 114: 457–464.
   PubMed Web of Science ®Google Scholar
• Hulka BS, Griffith JD, Wilcosky TC (1990). Overview of biological markers. In: Biological Markers in Epidemiology, Oxford University Press, New York. pp. 3–15.
   Google Scholar
• Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65: 7065–7070.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zheng X, Xu X, Zhou Q, Yan H, Zhang X, Lu B, Wu C, Ju J (2011). Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One 6: e23271.
   Web of Science ®Google Scholar
• Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO (2009). Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res. 11: R44.
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141: 672–675.
   PubMed Web of Science ®Google Scholar
• Lee JA, Lee HY, Lee ES, Kim I, Bae JW (2011). Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J. Breast Cancer 14: 269–275.
   PubMed Web of Science ®Google Scholar
• Li J, Li X, Li Y, Yang H, Wang L, Qin Y, Liu H, Fu L, Guan XY (2013). cell-specific detection of miR-375 downregulation for predicting the prognosis of esophageal squamous cell carcinoma by miRNA in situ hybridization. PLoS One 8: e53582.
   PubMed Web of Science ®Google Scholar
• Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A (2010). Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomark. Prev. 19: 1766–1774.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY (2011). A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47: 784–791.
   PubMed Web of Science ®Google Scholar
• Longley DB, Allen WL, Johnston PG (2006). Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim. Biophys. Acta 1766: 184–196.
   PubMed Web of Science ®Google Scholar
• Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H (2007). Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res. 67: 10117–10122.
   PubMed Web of Science ®Google Scholar
• Manne U, Srivastava RG, Srivastava S (2005). Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov. Today 10: 965–976.
   PubMed Web of Science ®Google Scholar
• Manne U, Shanmugam C, Bovell L, Katkoori VR, Bumpers HL (2010). MiRNAs as biomarkers for management of patients with colorectal cancer. Biomark. Med. 4: 761–770.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358: 1919–1928.
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113–2129.
   PubMed Web of Science ®Google Scholar
• Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, Guadagnoli M, Bonanno E, Muto G, Frajese GV, De Maria R, Spagnoli LG, Farace MG, Ciafre SA (2008). The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029.
   PubMed Web of Science ®Google Scholar
• Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG, Alevizos I (2010). Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 16: 34–38.
   PubMed Web of Science ®Google Scholar
• Millar AA, Waterhouse PM (2005). Plant and animal microRNAs: similarities and differences. Funct. Integr. Genom. 5: 129–135.
   PubMedGoogle Scholar
• Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR (2007). A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl. Acad. Sci. USA 104: 13513–13518.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25: 2537–2545.
   PubMed Web of Science ®Google Scholar
• Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J (2006). Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genom. Proteom. 3: 317–324.
   PubMedGoogle Scholar
• Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Rocken C, Ebert MP, Kwok TT, Sung JJ (2009). MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br. J. Cancer 101: 699–706.
   PubMed Web of Science ®Google Scholar
• Nishida N, Yamashita S, Mimori K, Sudo T, Tanaka F, Shibata K, Yamamoto H, Ishii H, Doki Y, Mori M (2012). MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. Ann. Surg. Oncol. 19: 3065–3071.
   PubMed Web of Science ®Google Scholar
• Olivieri F, Antonicelli R, Capogrossi MC, Procopio AD (2012). Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: an exciting challenge. Int. J. Cardiol. doi: 10.1016/j.ijcard.2012.1011.1103. E-pub ahead of print.
   Google Scholar
• Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15: 5473–5477.
   PubMed Web of Science ®Google Scholar
• Perera FP, Weinstein IB (2000). Molecular epidemiology: recent advances and future directions. Carcinogenesis 21: 517–524.
   PubMed Web of Science ®Google Scholar
• Perera RJ, Ray A (2007). MicroRNAs in the search for understanding human diseases. BioDrugs 21: 97–104.
   PubMed Web of Science ®Google Scholar
• Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y (2013). Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J. Transl. Med. 11: 10.
   PubMed Web of Science ®Google Scholar
• Quesne JL, Jones J, Warren J, Dawson SJ, Ali HR, Bardwell H, Blows F, Pharoah P, Caldas C (2012). Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J. Pathol. 227: 306–314.
   PubMed Web of Science ®Google Scholar
• Richart RM (1995). Screening. The next century. Cancer 76 (Supp. 10): 1919–1927.
   Web of Science ®Google Scholar
• Roberti A, La Sala D, Cinti C (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J. Cell. Physiol. 207: 571–581.
   PubMed Web of Science ®Google Scholar
• Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM (2006). MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 24: 4677–4684.
   PubMed Web of Science ®Google Scholar
• Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce C, Harris CC (2008). MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299: 425–436.
   PubMed Web of Science ®Google Scholar
• Shen J, Stass SA, Jiang F (2013). MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 329: 125–136.
   PubMed Web of Science ®Google Scholar
• Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007). MiR-21-mediated tumor growth. Oncogene 26: 2799–2803.
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J (2008). MiR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res. 14: 8080–8086.
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J (2009). Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28: 4065–4074.
   PubMed Web of Science ®Google Scholar
• Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J (2010). Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer 9: 96.
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Steitz JA (2007). AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell 128: 1105–1118.
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA (2007). Switching from repression to activation: microRNAs can up-regulate translation. Science 318: 1931–1934.
   PubMed Web of Science ®Google Scholar
• Vasudevan S, Tong Y, Steitz JA (2008). Cell-cycle control of microRNA-mediated translation regulation. Cell Cycle 7: 1545–1549.
   PubMed Web of Science ®Google Scholar
• Visone R, Veronese A, Balatti V, Croce CM (2012). MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia. Oncotarget 3: 195–202.
   PubMed Web of Science ®Google Scholar
• Wagner JA, Srivastava S (2002). Overview of biomarkers and surrogate endpoints in drug development. Dis. Markers 18: 41–46.
   PubMed Web of Science ®Google Scholar
• Wang CJ, Stratmann J, Zhou ZG, Sun XF (2010). Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer 10: 616.
   PubMed Web of Science ®Google Scholar
• Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucl. Acids Res. 37: 2584–2595.
   PubMed Web of Science ®Google Scholar
• Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M (2006). Prognostic values of microRNAs in colorectal cancer. Biomark. Insights 2: 113–121.
   PubMedGoogle Scholar
• Yamashita S, Yamamoto H, Mimori K, Nishida N, Takahashi H, Haraguchi N, Tanaka F, Shibata K, Sekimoto M, Ishii H, Doki Y, Mori M (2012). MicroRNA-372 is associated with poor prognosis in colorectal cancer. Oncology 82: 205–212.
   PubMed Web of Science ®Google Scholar
• Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chaerkady R, Beer MA, Mendell JT, Pandey A (2009). Identification of miR-21 targets in breast cancer cells using a quantitative proteomic approach. Proteomics 9: 1374–1384.
   PubMed Web of Science ®Google Scholar
• Young DD, Connelly M, Grohmann C, Deiters A (2010). Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 132: 7976–7981.
   PubMed Web of Science ®Google Scholar
• Zaman MS, Shahryari V, Deng G, Thamminana S, Saini S, Majid S, Chang I, Hirata H, Ueno K, Yamamura S, Singh K, Tanaka Y, Tabatabai ZL, Dahiya R (2012). Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 7: e31060.
   PubMed Web of Science ®Google Scholar
• Zen K, Zhang CY (2012). Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 32: 326–348.
   PubMed Web of Science ®Google Scholar
• Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao K R Liu P, Xu W, Li JY (2012). miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33: 1294–1301.
   PubMed Web of Science ®Google Scholar